mitochondrial-dysfunction-neurodegeneration-comparison

Migration, Crosslink

📖

mitochondrial-dysfunction-neurodegeneration-comparison

active

wiki page Created: 2026-04-02T07:20:13 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-diseases-mitochondrial-dysfunction-

📖 Wiki Page

disease2873 wordssynced 2026-04-02

Mitochondrial Dysfunction in Neurodegenerative Diseases Comparison

Mitochondrial dysfunction is a shared pathological feature across multiple neurodegenerative diseases. This comparison examines how mitochondrial deficits contribute to Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Huntington's Disease (HD).

Overview

Mitochondria are essential for neuronal survival, providing ATP energy, regulating calcium homeostasis, and controlling apoptotic pathways. All five neurodegenerative diseases exhibit mitochondrial abnormalities that contribute to neuronal dysfunction and death.

flowchart TD A["Genetic/Environmental<br/>Insults"] --> B["Mitochondrial Dysfunction"] B --> C["ATP Depletion"] B --> D["Oxidative Stress"] B --> E["Calcium Dysregulation"] B --> F["Apoptosis"] C --> G[" neuronal Death"] D --> G E --> G F --> G B --> H["AD: Abeta/APP, Complex I/IV"] B --> I["PD: Complex I, PINK1/Parkin"] B --> J["ALS: SOD1, TDP-43"] B --> K["FTD: Tau, FUS"] B --> L["HD: Mutant HTT"] style A fill:#1a0a1f,stroke:#333,color:#e0e0e0 style G fill:#3e2200,stroke:#333,color:#e0e0e0

Comparison Matrix

...

Mitochondrial Dysfunction in Neurodegenerative Diseases Comparison

Mitochondrial dysfunction is a shared pathological feature across multiple neurodegenerative diseases. This comparison examines how mitochondrial deficits contribute to Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Huntington's Disease (HD).

Overview

Mitochondria are essential for neuronal survival, providing ATP energy, regulating calcium homeostasis, and controlling apoptotic pathways. All five neurodegenerative diseases exhibit mitochondrial abnormalities that contribute to neuronal dysfunction and death.

Mermaid diagram (expand to render)

Comparison Matrix

| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | Frontotemporal Dementia | Huntington's Disease |
|---------|-------------------|---------------------|-----|------------------------|---------------------|
| Primary Mitochondrial Defect | Complex I, III, IV deficiency | Complex I deficiency | Multiple complex defects | Variable, complex IV | Complex IV deficiency |
| Key Proteins | Aβ, APP, tau | α-synuclein, PINK1, Parkin | SOD1, TDP-43, FUS | Tau, FUS | Mutant huntingtin |
| mtDNA Changes | Reduced copy number, mutations | Mutations, deletions | Reduced copy number | Mutations in some cases | CAG repeat affects mtDNA |
| Mitophagy Impairment | Yes | Yes (PINK1/Parkin) | Yes | Yes | Yes |
| OXPHOS Deficiency | Complex I, III, IV | Complex I prominent | Multiple complexes | Complex IV | Complex IV |
| Oxidative Stress | Severe | High | High | Moderate-High | Severe |
| Fission/Fusion | Imbalanced | Impaired | Dysregulated | Affected | Dysregulated |
| Regional Vulnerability | Cortex, hippocampus | Substantia nigra | Motor neurons | Frontal/temporal cortex | Striatum, cortex |

Disease-Specific Mechanisms

Alzheimer's Disease

Mitochondrial dysfunction in AD involves multiple mechanisms. Amyloid-beta (Aβ) accumulates within mitochondria, directly impairing complex IV (cytochrome c oxidase) activity and reducing ATP production[@bhat2019]. The APP protein localizes to mitochondrial membranes, causing mitochondrial stress and increasing reactive oxygen species (ROS) production[@devi2017]. Additionally, tau pathology disrupts mitochondrial transport along axons, preventing proper distribution of mitochondria to synaptic terminals where energy demand is highest[@barrientos2003].

Key mitochondrial features in AD:

Reduced cytochrome c oxidase (Complex IV) activity in platelets and brain tissue
Increased mitochondrial Aβ accumulation with disease progression
Impaired mitochondrial dynamics (fission/fusion imbalance)
Altered mitochondrial calcium handling
mtDNA mutations and reduced copy number

Parkinson's Disease

PD shows the most direct link to mitochondrial dysfunction, with Complex I deficiency being a hallmark finding[@schapira1989]. The identification of PD genes encoding mitochondrial proteins (PINK1, Parkin, DJ-1) established mitochondrial quality control as central to PD pathogenesis[@pickrell2015]. Environmental toxins that inhibit Complex I (MPTP, rotenone) cause parkinsonism, confirming the causal relationship[@winklhofer2009].

Key mitochondrial features in PD:

Selective Complex I deficiency in substantia nigra
Impaired PINK1/Parkin mitophagy pathway
DJ-1 mutations cause mitochondrial oxidative stress
Alpha-synuclein interacts with mitochondrial membranes
LRRK2 mutations affect mitochondrial dynamics

Amyotrophic Lateral Sclerosis

Mitochondrial dysfunction is an early event in ALS pathogenesis, with energy failure contributing to motor neuron degeneration[@da2021]. Mutations in SOD1 cause mitochondrial damage through toxic gain-of-function, while TDP-43 aggregation disrupts mitochondrial axonal transport[@federico2023]. The能量代谢 deficit in ALS motor neurons precedes clinical onset[@chaari2023].

Key mitochondrial features in ALS:

Morphologically abnormal mitochondria in motor neurons
Reduced Complex I, II, IV activities
Impaired mitochondrial calcium buffering
Disrupted mitochondrial axonal transport
Energy failure and increased ROS

Frontotemporal Dementia

FTD involves mitochondrial dysfunction, though it is less characterized than in AD or PD[@kosel2020]. Mutations in tau (MAPT) and FUS proteins affect mitochondrial function. Some FTD subtypes show complex IV deficiency and reduced mitochondrial respiratory capacity[@van2014]. The overlap between FTD and ALS (FTD-ALS spectrum) shares mitochondrial pathological mechanisms.

Key mitochondrial features in FTD:

Variable complex deficiencies depending on subtype
Mitochondrial dysfunction in tauopathy
FUS protein aggregates impair mitochondrial function
Reduced mitochondrial DNA integrity in some cases
Energy metabolism deficits in frontal cortex

Huntington's Disease

HD features prominent mitochondrial dysfunction as a core pathogenic mechanism[@staventrate2022]. Mutant huntingtin directly impairs mitochondrial function by: (1) reducing PGC-1α expression (mitochondrial biogenesis regulator), (2) impairing mitochondrial dynamics, (3) affecting mitochondrial DNA repair, and (4) reducing complex IV activity[@gu2016]. The CAG repeat expansion in the HTT gene leads to toxic gain-of-function that disrupts multiple aspects of mitochondrial biology.

Key mitochondrial features in HD:

Reduced Complex IV activity in striatum and cortex
Impaired mitochondrial biogenesis (PGC-1α dysfunction)
Mutant huntingtin disrupts mitochondrial transport
Elevated mitochondrial DNA damage
Decreased mitochondrial calcium handling capacity
Altered mitochondrial permeability transition

PGC-1α and Mitochondrial Biogenesis

The peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) is a master regulator of mitochondrial biogenesis. This transcriptional coactivator controls the expression of nuclear-encoded mitochondrial genes through activation of transcription factors including NRF-1, NRF-2, and ERRα[@liu2019].

In Huntington's disease, mutant huntingtin binds to and represses PGC-1α activity, leading to downregulation of mitochondrial biogenesis genes. This creates a vicious cycle where fewer mitochondria are produced while existing ones become progressively damaged.

Similar PGC-1α dysfunction occurs in other neurodegenerative diseases:

AD: Reduced PGC-1α expression contributes to mitochondrial depletion
PD: PGC-1α pathway is disrupted, affecting mitochondrial quality control
ALS: PGC-1α dysregulation contributes to motor neuron vulnerability
FTD: Variable PGC-1α impairment depending on subtype

Complex I Deficiency Across Diseases

Complex I (NADH:ubiquinone oxidoreductase) is the largest complex of the electron transport chain. Its deficiency is a hallmark of Parkinson's disease but also occurs in other neurodegenerative conditions:

Parkinson's Disease: The most severe Complex I deficiency, particularly in substantia nigra. This deficiency is linked to both genetic factors (PINK1, Parkin mutations) and environmental toxins (MPTP, rotenone)[@schapira1989].

Alzheimer's Disease: Complex I deficiency is present but less severe than Complex IV. Contributes to overall OXPHOS impairment[@reddy2011].

ALS: Multiple complex deficiencies including Complex I. Early energy deficit in motor neurons precedes clinical symptoms[@da2021].

FTD: Variable Complex I deficiency depending on subtype and individual variation[@van2014].

Huntington's Disease: Complex I activity is reduced, contributing to the overall OXPHOS deficit[@gu2016].

Shared Pathomechanisms

1. ATP Depletion

All five diseases exhibit reduced ATP production due to impaired oxidative phosphorylation (OXPHOS). Neurons have high energy demands, making them particularly vulnerable to ATP deficits. The resulting energy failure leads to:

Ion pump dysfunction
Synaptic failure
Eventually, neuronal death

2. Oxidative Stress

Mitochondrial dysfunction generates excess reactive oxygen species (ROS). Neurons are especially vulnerable due to high lipid content and relatively limited antioxidant capacity. Common oxidative markers include:

Increased lipid peroxidation
DNA oxidation (8-OHdG)
Protein carbonylation
Altered antioxidant defenses

3. Calcium Dysregulation

Mitochondria serve as calcium buffers. Dysfunction leads to impaired calcium handling, which:

Triggers excitotoxicity
Activates calpains and caspases
Disrupts synaptic function
Promotes apoptotic pathways

4. Mitophagy Impairment

Quality control via mitophagy is compromised in all five diseases. Failure to remove damaged mitochondria leads to accumulation of dysfunctional mitochondria that:

Produce more ROS
Release pro-apoptotic factors
Fail to meet cellular energy demands

5. Mitochondrial Dynamics

Fission and fusion imbalances occur across all conditions. Excessive fission or impaired fusion results in:

Fragmented mitochondria
Impaired distribution
Reduced mitochondrial network connectivity
Decreased mitochondrial function

Therapeutic Implications

| Approach | AD | PD | ALS | FTD | HD |
|----------|----|----|-----|-----|-----|
| CoQ10 | + | +++ | + | + | ++ |
| Mitochondrial Biogenesis (PGC-1α) | + | + | + | + | +++ |
| Antioxidants | ++ | ++ | ++ | + | ++ |
| Mitophagy Modulators | + | +++ | ++ | + | ++ |
| Complex IV Bypass | + | - | - | - | + |

Legend: +++ = strong evidence, ++ = moderate evidence, + = preclinical/limited, - = not applicable

Cross-Reference Links

Disease Pages

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[ALS](/diseases/als)
[Frontotemporal Dementia](/diseases/frontotemporal-dementia)
[Huntington's Disease](/diseases/huntington-disease)

Mechanism Pages

[Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction-pathway)
[Mitochondrial Dynamics Pathway](/mechanisms/mitochondrial-dynamics-pathway)
[Mitochondrial Fusion in Neurodegeneration](/mechanisms/mitochondrial-fusion-neurodegeneration)
[Oxidative Stress Pathway](/mechanisms/oxidative-stress-neurodegeneration)
[Apoptosis Pathway](/mechanisms/apoptosis-neurodegeneration)

Gene Pages

[PINK1](/genes/pink1)
[PARKIN](/genes/parkin)
[DJ-1](/genes/dj1)
[LRRK2](/genes/lrrk2)
[SNCA](/genes/snca)
[SOD1](/genes/sod1)
[TARDBP](/genes/tardbp)
[FUS](/genes/fus)
[MAPT](/genes/mapt)
[HTT](/genes/htt)

Entity Pages

[Mitochondria](/entities/mitochondria)
[Reactive Oxygen Species](/entities/reactive-oxygen-species)
[Neurons](/entities/neurons)
[Apoptosis](/entities/apoptosis)

Biomarkers

| Biomarker | AD | PD | ALS | FTD | HD |
|-----------|----|----|-----|-----|-----|
| Lactate | Elevated | May be elevated | Elevated | Variable | Elevated |
| Creatine Kinase | Normal | Normal | Elevated (CK) | Normal | Normal |
| mtDNA Copy Number | Reduced | May be reduced | Reduced | Variable | Reduced |
| Complex I Activity | Reduced | Severely reduced | Reduced | Variable | Reduced |
| Complex IV Activity | Reduced | Reduced | Reduced | Reduced | Severely reduced |

Environmental and Lifestyle Factors

Toxins and Mitochondrial Dysfunction

Environmental toxins provide crucial insights into mitochondrial pathogenesis across neurodegenerative diseases:

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine): This toxin specifically inhibits Complex I and causes parkinsonism in humans and animal models. MPTP-induced parkinsonism closely mimics idiopathic PD, demonstrating that mitochondrial Complex I deficiency is sufficient to cause dopaminergic neuron loss[@winklhofer2009].

Rotenone: A pesticide that inhibits Complex I. Chronic rotenone exposure in rodents produces parkinsonian features including alpha-synuclein aggregation and dopaminergic neuron loss.

Paraquat: Another herbicide that generates oxidative stress and impairs mitochondrial function. Associated with increased PD risk.

6-OHDA (6-hydroxydopamine): Used in animal models of PD. This toxin selectively destroys catecholaminergic neurons through oxidative mechanisms.

Kainic Acid: An excitotoxin used in models of ALS and temporal lobe epilepsy. Causes mitochondrial dysfunction and seizure activity.

Protective Factors and Lifestyle Interventions

Several lifestyle factors may mitigate mitochondrial dysfunction:

Caloric Restriction: Activates autophagy and mitophagy, improves mitochondrial function, and extends lifespan in multiple species. May reduce neurodegenerative disease risk.

Exercise: Increases mitochondrial biogenesis through PGC-1α activation, improves mitochondrial dynamics, and enhances antioxidant defenses.

Ketogenic Diet: Provides alternative fuel (ketones) that may bypass mitochondrial defects. Shows benefit in some epilepsy models and is being explored for neurodegenerative diseases.

Coenzyme Q10: Electron carrier and antioxidant. Has shown promise in PD and mitochondrial diseases. The CoQ10 molecule transfers electrons between Complexes I/II and III.

Alpha-lipoic Acid: Antioxidant that regenerates other antioxidants including vitamin C, vitamin E, and glutathione. Shows neuroprotective properties in multiple models.

Melatonin: Hormone with antioxidant properties. Protects mitochondria from oxidative damage and may improve sleep quality in neurodegenerative diseases.

Molecular Mechanisms of Neuronal Vulnerability

Why Neurons Are Particularly Vulnerable

Neurons have unique characteristics that make them especially susceptible to mitochondrial dysfunction:

High Energy Demand: Neurons have constant ATP requirements for maintaining ion gradients, neurotransmitter release, and synaptic plasticity. The brain represents only 2% of body weight but consumes 20% of oxygen and energy.

Post-Mitotic Nature: Unlike other cells, neurons cannot divide to replace damaged mitochondria. Accumulated mitochondrial damage persists throughout life.

Axonal Transport: Mitochondria must be transported long distances (up to one meter in motor neurons). Disruption of transport leads to localized energy deficits at synapses and distal axons.

Calcium Handling: Neurons experience frequent calcium fluctuations during synaptic activity. Mitochondrial calcium buffering is crucial for maintaining calcium homeostasis.

Iron Accumulation: Aging neurons accumulate iron, which catalyzes oxidative stress through Fenton reactions. Mitochondria are particularly susceptible to iron-induced damage.

Regional Vulnerability Patterns

The selective vulnerability of specific brain regions reflects their mitochondrial susceptibility:

Substantia Nigra Pars Compacta (PD): Dopaminergic neurons have high metabolic demands, specific iron metabolism, and unique calcium handling. Complex I deficiency is most pronounced in this region.

Motor Cortex and Spinal Cord (ALS): Motor neurons have extremely long axons requiring high mitochondrial density. Their high firing rates create substantial energy demands.

Hippocampus (AD): The CA1 region and entorhinal cortex are early sites of AD pathology. These neurons are highly active in memory formation and consolidation.

Frontal and Temporal Cortices (FTD): These regions show early atrophy in FTD. Mitochondrial dysfunction contributes to progressive cortical degeneration.

Striatum (HD): Medium spiny neurons are particularly vulnerable due to their high metabolic activity and GABAergic signaling requirements.

Genetic Factors and Mitochondrial Interactions

Nuclear-Mitochondrial Crosstalk

Mitochondrial function is regulated by both mitochondrial DNA (mtDNA) and nuclear DNA. Over 1,000 nuclear-encoded proteins are imported into mitochondria, creating extensive crosstalk between the two genomes.

mtDNA: The mitochondrial genome encodes 13 essential OXPHOS subunits, 22 tRNAs, and 2 rRNAs. Mutations in mtDNA cause several neurodegenerative phenotypes.

Nuclear Mitochondrial Proteins: PGC-1α, TFAM, NRF1, NRF2 are nuclear-encoded regulators of mitochondrial biogenesis and function.

Specific Genetic Interactions

PARK Genes: Several PD genes encode mitochondrial proteins:

PINK1 (PARK6): Kinase that initiates mitophagy
PARK2 (Parkin): E3 ubiquitin ligase for mitophagy
PARK7 (DJ-1): Oxidative stress sensor
PARK8 (LRRK2): Affects mitochondrial dynamics

SOD1 (ALS): Mutations cause toxic gain-of-function affecting mitochondria. SOD1 aggregates disrupt mitochondrial ultrastructure and function.

HTT (HD): Mutant huntingtin represses PGC-1α, impairs mitochondrial transport, and disrupts mitochondrial DNA repair.

MAPT (FTD): Tau mutations affect mitochondrial axonal transport. Tau pathology is associated with mitochondrial dysfunction.

Sex Differences in Mitochondrial Vulnerability

Emerging evidence suggests sex differences in mitochondrial dysfunction across neurodegenerative diseases:

Estrogen Effects: Estrogen has neuroprotective effects through mitochondrial modulation. It enhances mitochondrial biogenesis, improves OXPHOS efficiency, and reduces ROS production.

Women's Protection in PD: Women have lower PD risk, possibly related to estrogen-mediated mitochondrial protection. Estrogen activates estrogen receptors that upregulate mitochondrial biogenesis genes.

Men's Higher Risk in HD: Male patients may show more rapid progression. Sex-specific differences in mitochondrial responses to mutant huntingtin have been observed.

Hormone Therapy: Hormone replacement therapy may influence mitochondrial outcomes, though this remains an area of active investigation.

Animal Models and Research Tools

Genetic Models

C. elegans: Simple model for studying mitochondrial genetics and mitophagy. Short lifespan allows rapid screening of interventions.

Drosophila melanogaster: Genetic models for PD (PINK1, parkin mutants), ALS (SOD1), and HD (HTT expansions). Powerful genetic tools available.

Zebrafish: Useful for studying mitochondrial development and neurodevelopment. Transparent embryos allow visualization of mitochondrial dynamics.

Rodent Models: Most comprehensive models for neurodegenerative diseases. Include:

MPTP/6-OHDA models for PD
APP/PS1, 3xTg-AD for AD
SOD1, TDP-43 models for ALS
R6/1, Hdh knock-in models for HD
Tau P301S models for FTD

Pharmacological Models

Complex I Inhibitors: MPTP, rotenone, and paraquat induce PD-like pathology in animals. These models establish mitochondrial dysfunction as sufficient for neurodegeneration.

Complex IV Inhibitors: Sodium azide and cyanide produce brain-specific energy failure. Used to model AD-related mitochondrial deficits.

Oxidative Stress Models: Various agents (6-OHDA, kainic acid, malonate) induce oxidative damage relevant to multiple neurodegenerative conditions.

Therapeutic Targets and Drug Development

The understanding of mitochondrial dysfunction has identified several therapeutic targets:

Mitochondrial Biogenesis Activators:

PGC-1α agonists
AMPK activators (e.g., AICAR)
SIRT1 activators (resveratrol)

Mitophagy Enhancers:

PINK1 activators
Parkin activators
Autophagy inducers

Antioxidants:

CoQ10 and analogs
MitoQ (mitochondria-targeted antioxidant)
SS-31 (mitochondria-targeted peptide)

Metabolic Modulators:

Ketogenic agents
Dichloroacetate (PDH activator)
Glucose metabolism modulators

Ion Channel Modulators:

Calcium channel blockers
Mitochondrial calcium uniporter modulators
Potassium channel activators

Conclusion

Mitochondrial dysfunction represents a convergent pathogenic mechanism across neurodegenerative diseases. While each disease has unique proteinopathies and vulnerable brain regions, the mitochondrial defects—ATP depletion, oxidative stress, calcium dysregulation, mitophagy impairment, and dynamics imbalance—are shared. This understanding opens therapeutic avenues targeting mitochondria, though delivery and specificity remain significant challenges.

References

[Lin MT, Beal MF. Mitochondrial dysfunction in neurodegenerative disease. Nature Reviews Neurology. 2006.](https://pubmed.ncbi.nlm.nih.gov/16759986/)

[Schapira AH, et al. Mitochondrial complex I deficiency in Parkinson's disease. Lancet. 1989.](https://pubmed.ncbi.nlm.nih.gov/2547445/)

[Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron. 2015.](https://pubmed.ncbi.nlm.nih.gov/25943887/)

[Bhat S, et al. Mitochondrial dysfunction in Alzheimer's disease. Biochim Biophys Acta Mol Basis Dis. 2019.](https://pubmed.ncbi.nlm.nih.gov/31170383/)

[Kosel F, et al. Mitochondria and mitochondrial DNA in frontotemporal dementia and Alzheimer's disease. J Neurochem. 2020.](https://pubmed.ncbi.nlm.nih.gov/32060957/)

[Da Silva CC, et al. Mitochondrial dysfunction in amyotrophic lateral sclerosis. Int J Mol Sci. 2021.](https://pubmed.ncbi.nlm.nih.gov/34072609/)

[Staventrate C, et al. Mitochondrial dysfunction in Huntington's disease. Mol Neurobiol. 2022.](https://pubmed.ncbi.nlm.nih.gov/35211897/)

[Gu M, et al. Mitochondrial deficiency in Huntington's disease. Nat Rev Dis Primers. 2016.](https://pubmed.ncbi.nlm.nih.gov/27003656/)

[Winklhofer KF, Haass C. Mitochondrial dysfunction in Parkinson's disease. Biochim Biophys Acta Mol Basis Dis. 2009.](https://pubmed.ncbi.nlm.nih.gov/19118507/)

[Federico A, et al. Mitochondrial dysfunction and ALS. Ageing Res Rev. 2023.](https://pubmed.ncbi.nlm.nih.gov/37178901/)

[Barrientos A, et al. Molecular basis of mitochondrial disease in Alzheimer's disease. Ann Neurol. 2003.](https://pubmed.ncbi.nlm.nih.gov/12838540/)

[Morovati M, et al. Mitochondrial dynamics and quality control in neurodegeneration. J Cell Physiol. 2019.](https://pubmed.ncbi.nlm.nih.gov/31190123/)

[Wu Z, et al. Mitochondrial fission and fusion in neurodegenerative diseases. Brain Res Bull. 2019.](https://pubmed.ncbi.nlm.nih.gov/30685567/)

[Chaari M, et al. The role of mitochondrial dysfunction in ALS pathogenesis. Front Cell Neurosci. 2023.](https://pubmed.ncbi.nlm.nih.gov/37662666/)

[Liu J, et al. Mitochondrial bioenergetics and dynamics in Huntington's disease. Eur J Pharmacol. 2019.](https://pubmed.ncbi.nlm.nih.gov/31129128/)

[Van De Velde M, et al. Mitochondrial dysfunction in frontotemporal lobar degeneration. Brain Pathol. 2014.](https://pubmed.ncbi.nlm.nih.gov/24506733/)

[Reddy PH, et al. Mitochondrial dysfunction in Alzheimer's and Parkinson's disease. Biochim Biophys Acta Bioenerg. 2011.](https://pubmed.ncbi.nlm.nih.gov/21238598/)

[Devi L, et al. Mitochondrial impairments in Alzheimer's disease. J Alzheimers Dis. 2017.](https://pubmed.ncbi.nlm.nih.gov/28059769/)

[Iwaki H, et al. Genetic variation in mitochondrial pathways and Parkinson's disease risk. Ann Neurol. 2019.](https://pubmed.ncbi.nlm.nih.gov/31063623/)

[Chu Y, et al. Mitochondrial changes in aging and neurodegenerative diseases. J Neuropathol Exp Neurol. 2019.](https://pubmed.ncbi.nlm.nih.gov/30649326/)

📖 View canonical wiki page →

Related Entities

diseases-mitochondrial-dysfunction-neurodegeneration-comparison

▸Metadataorigin_type: v1_polymorphic_backfill

slug	diseases-mitochondrial-dysfunction-neurodegeneration-comparison
kg_node_id	None
entity_type	disease
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-a04625bcb772
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'diseases-mitochondrial-dysfunction-neurodegeneration-comparison'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

2828

Outgoing

3160

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

mitochondrial-dysfunction-neurodegeneration-comparison

Mitochondrial Dysfunction in Neurodegenerative Diseases Comparison

Overview

Comparison Matrix

Mitochondrial Dysfunction in Neurodegenerative Diseases Comparison

Overview

Comparison Matrix

Disease-Specific Mechanisms

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Frontotemporal Dementia

Huntington's Disease

PGC-1α and Mitochondrial Biogenesis

Complex I Deficiency Across Diseases

Shared Pathomechanisms

1. ATP Depletion

2. Oxidative Stress

3. Calcium Dysregulation

4. Mitophagy Impairment

5. Mitochondrial Dynamics

Therapeutic Implications

Cross-Reference Links

Disease Pages

Mechanism Pages

Gene Pages

Entity Pages

Biomarkers

Environmental and Lifestyle Factors

Toxins and Mitochondrial Dysfunction

Protective Factors and Lifestyle Interventions

Molecular Mechanisms of Neuronal Vulnerability

Why Neurons Are Particularly Vulnerable

Regional Vulnerability Patterns

Genetic Factors and Mitochondrial Interactions

Nuclear-Mitochondrial Crosstalk

Specific Genetic Interactions

Sex Differences in Mitochondrial Vulnerability

Animal Models and Research Tools

Genetic Models

Pharmacological Models

Therapeutic Targets and Drug Development

Conclusion

References

💬 Discussion